Lawrence Serfaty

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Improved survival after variceal bleeding in patients with cirrhosis over the past two decades

Nicolas Carbonell, Arnaud Pauwels, Lawrence Serfaty et al. · Hepatology · 2004 · 850 citations · Full text

Medicine, Internal Medicine, Gastroenterology +13

Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy

Olivier Chazouillères, Dominique Wendum, Lawrence Serfaty et al. · Hepatology · 1998 · 753 citations

Medicine, Internal Medicine, Pathology +17

The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids

Alexandre Louvet, Sylvie Naveau, Marcelle Abdelnour et al. · Hepatology · 2007 · 725 citations · Full text

Medicine, Pharmacology, Hepatic Pharmacotherapy +16

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

Vlad Ratziu, Philippe Giral, Sophie Jacqueminet et al. · Gastroenterology · 2008 · 622 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9